Development and testing of a first-in-class series of macrocyclic ATR inhibitors for cancer treatment

被引：0

作者：

Rocca, S. ^{[1
]}

Hansbarger, M. ^{[1
]}

Gill, T. ^{[1
]}

George, E. ^{[2
]}

Rom, I. ^{[1
]}

Weinstein, J. ^{[1
]}

Breslin, H. ^{[3
]}

Jia, L. ^{[3
]}

Simpkins, F. ^{[4
]}

Brown, E. ^{[5
,6
]}

Gilad, O. ^{[7
]}

机构：

[1] Aprea Therapeut Inc, Biol, Doylestown, PA USA

[2] Moffit Canc Ctr, Gynecol Oncol Program, Tampa, FL USA

[3] Aprea Therapeut Inc, Med Chem, Doylestown, PA USA

[4] Univ Penn, Dept Obstet & Gynecol, Perelman Sch Med, Ovarian Canc Res Ctr,Div Gynecol Oncol, Philadelphia, PA 19104 USA

[5] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA

[6] Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA

[7] Aprea Therapeut Inc, Co Management, Doylestown, PA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷

关键词：

D O I：

10.1016/j.ejca.2024.114849

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PB324

引用

页码：S126 / S127

页数：2

共 50 条

[41] Discovery of the First-in-Class G9a/GLP Covalent Inhibitors
Park, Kwang-Su
Xiong, Yan
Yim, Hyerin
Velez, Julia
Babault, Nicolas
Kumar, Prashasti
Liu, Jing
Jin, Jian
JOURNAL OF MEDICINAL CHEMISTRY, 2022, : 10506 - 10522
[42] First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8
Fiorentino, Francesco
Sementilli, Sara
Menna, Martina
Turrisi, Federica
Tomassi, Stefano
Pellegrini, Francesca Romana
Iuzzolino, Angela
D'Acunzo, Francesca
Feoli, Alessandra
Wapenaar, Hannah
Taraglio, Sophie
Fraschetti, Caterina
Del Bufalo, Donatella
Sbardella, Gianluca
Dekker, Frank J.
Paiardini, Alessandro
Trisciuoglio, Daniela
Mai, Antonello
Rotili, Dante
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (10) : 6591 - 6616
[43] The LEDGINs: first-in-class allosteric HIV-1 integrase inhibitors
Desimmie, B.
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2012, 17 : 14 - 14
[44] First-in-class inhibitors of SbnA reduce siderophore production in Staphylococcus aureus
Hijazi, Sarah
Cozzi, Monica
Asgharpour, Somayeh
De Bei, Omar
Faggiano, Serena
Marchesani, Francesco
Ronda, Luca
Marchetti, Marialaura
Gianquinto, Eleonora
Failla, Mariacristina
Treves, Gauthier
Lazzarato, Loretta
Spyrakis, Francesca
Campanini, Barbara
Frangipani, Emanuela
Bettati, Stefano
FEBS JOURNAL, 2025,
[45] First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer
Abbott, Joshua M.
Zhou, Qiong
Esquer, Hector
Pike, Laura
Broneske, Travis P.
Rinaldetti, Sebastien
Abraham, Adedoyin D.
Ramirez, Dominique A.
Lunghofer, Paul J.
Pitts, Todd M.
Regan, Daniel P.
Tan, Aik Choon
Gustafson, Daniel L.
Messersmith, Wells A.
LaBarbera, Daniel V.
MOLECULAR CANCER THERAPEUTICS, 2020, 19 (08) : 1598 - 1612
[46] DEVELOPMENT OF A NOVEL FIRST-IN-CLASS ORAL INHIBITOR OF THE NOTCH PATHWAY
Lehal, R.
Frismantas, V.
Reinmuller, V.
Turcatti, G.
Bourquin, J. P.
Radtke, F.
HAEMATOLOGICA, 2016, 101 : 29 - 29
[47] Bendavia, a first-in-class mitochondrial protectant, for the treatment of heart failure
Sabbah, H.
CARDIOLOGY, 2013, 126 : 402 - 402
[48] FIRST-IN-CLASS CANCER THERAPEUTICS TARGETING THE DNA DAMAGE RESPONSE
Robertson, Adam
Prikrylova, Terezia
Lancero, Hope
Wilson, Christy
Petritsch, Claudia
NEURO-ONCOLOGY, 2023, 25
[49] First-in-class T cell engager approved for lung cancer
不详
NATURE BIOTECHNOLOGY, 2024, 42 (06) : 826 - 826
[50] Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia
Fancher, Karen M.
Lally-Montgomery, Zachary C.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1467 - 1472

← 1 2 3 4 5 →